1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Drugs In Development, 2022, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Pheochromocytoma - Overview
- Pheochromocytoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Pheochromocytoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pheochromocytoma - Companies Involved in Therapeutics Development
- Advanced Accelerator Applications SA
- AstraZeneca Plc
- Chimerix Inc
- Enterome Bioscience SA
- Exelixis Inc
- Gibson Oncology LLC
- Ipsen SA
- Jubilant DraxImage Inc
- Lixte Biotechnology Holdings Inc
- Merck & Co Inc
- Pfizer Inc
- Tarveda Therapeutics Inc
- Vyriad Inc
- Pheochromocytoma - Drug Profiles
- 211At-MABG - Drug Profile
- Product Description
- Mechanism Of Action
- belzutifan - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cabozantinib s-malate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EO-2401 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- iobenguane I 131 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lanreotide acetate PR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LB-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LMP-400 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lutetium Lu 177 dotatate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- olaparib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ONC-201 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PEN-221 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sunitinib malate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Voyager-V1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Pheochromocytoma - Dormant Projects
- Pheochromocytoma - Product Development Milestones
- Featured News & Press Releases
- Jul 27, 2021: Clinical trial of Belzutifan in pancreatic NETs and Pheo/Para
- May 28, 2020: Oncoceutics to present additional data at ASCO showing clinical benefit from ONC201 for Cancer Patients
- Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Pheochromocytoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, 2022
- Pheochromocytoma - Pipeline by AstraZeneca Plc, 2022
- Pheochromocytoma - Pipeline by Chimerix Inc, 2022
- Pheochromocytoma - Pipeline by Enterome Bioscience SA, 2022
- Pheochromocytoma - Pipeline by Exelixis Inc, 2022
- Pheochromocytoma - Pipeline by Gibson Oncology LLC, 2022
- Pheochromocytoma - Pipeline by Ipsen SA, 2022
- Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, 2022
- Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, 2022
- Pheochromocytoma - Pipeline by Merck & Co Inc, 2022
- Pheochromocytoma - Pipeline by Pfizer Inc, 2022
- Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, 2022
- Pheochromocytoma - Pipeline by Vyriad Inc, 2022
- Pheochromocytoma - Dormant Projects, 2022
- Number of Products under Development for Pheochromocytoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanced Accelerator Applications SA
- AstraZeneca Plc
- Chimerix Inc
- Enterome Bioscience SA
- Exelixis Inc
- Gibson Oncology LLC
- Ipsen SA
- Jubilant DraxImage Inc
- Lixte Biotechnology Holdings Inc
- Merck & Co Inc
- Pfizer Inc
- Tarveda Therapeutics Inc
- Vyriad Inc
